New Drug Application For Inhaled Treprostinil Submitted To The U.S. Food And Drug Administration
Wednesday, July 2nd, 2008
United
Therapeutics Corporation (Nasdaq: UTHR) and its wholly-owned subsidiary,
Lung Rx, Inc., announced the submission of a New Drug Application
(NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval
of an inhaled formulation of treprostinil (ITRE) for the treatment of
pulmonary arterial hypertension (PAH), a chronic, life-threatening disease.
The submission starts a 60-day period during which the FDA will examine the
application for completeness. If the FDA accepts the ITRE NDA for review,
then it is expected to be subject to the standard 10- to 12-month review
period before an action letter is issued.
"We believe that an inhaled formulation of treprostinil will be a very
desirable option for PAH patients," said Martine Rothblatt, Ph.D., United
Therapeutics’ Chairman and Chief Executive Officer. "The completion of the
NDA filing is a huge milestone in United Therapeutics’ quest to develop as
many formulations of treprostinil as possible to create better, more
convenient therapies to treat the debilitating effects of PAH along the
full spectrum of the disease."
The ITRE NDA is principally supported by data from the TRIUMPH-1 Phase
III clinical trial.
About TRIUMPH-1
TRIUMPH-1 (TReprostinil Sodium Inhalation Used in the Management of
Pulmonary Arterial Hypertension), was a randomized, double-blind, placebo-
controlled trial of patients with Generic levitra pills no prescription PAH. ITRE is prepared once per day and
administered in four daily inhalation sessions using the NEBU-TEC
Optineb(TM) ultrasonic nebulizer, with each inhalation session taking
approximately 1-2 minutes.
The TRIUMPH-1 clinical trial is one of the first pivotal trials to
assess the incremental benefit of an add-on therapy in PAH patients who are
already receiving an approved background therapy. The study population
consisted of 235 patients who were optimized on an approved oral therapy
for PAH, either bosentan (Tracleer(R)), an endothelin receptor antagonist,
or sildenafil (Revatio(R)), a phosphodiesterase-5 inhibitor. The majority
of patients were New York Heart Association (NYHA) Class III (~98%) of
varied etiologies, including idiopathic or familial PAH (~60%), collagen
vascular disease associated PAH (~30%), and PAH associated with HIV,
anorexigens or other associated conditions (~10%).
The primary efficacy endpoint of the TRIUMPH-1 clinical trial was the
change in six-minute walk (6MW) distance at 12 weeks measured at peak
exposure, defined by the trial protocol as 10-60 minutes after
administration of ITRE relative to baseline. Analysis of the TRIUMPH-1
clinical trial results confirmed an improvement in median 6MW distance of
approximately 20 meters (pBuy ultram pills | Buy lexapro without prescription | Buy generic acomplia